Single versus double application of vaginal dinoprostone: maternal factors affecting responsiveness

J Matern Fetal Neonatal Med. 2022 Dec;35(24):4763-4767. doi: 10.1080/14767058.2020.1863367. Epub 2021 Jan 31.

Abstract

Purpose: The aim of our study was to identify maternal characteristics of women who are responsive to the second application of vaginal dinoprostone in a cohort of patients with a low Bishop Score. Secondarily, we compared the outcome of the patients' response to a single application to that of the women's response to a double application.Materials and methods: This was a retrospective observational cohort study. Patients undergoing preinduction of labor with dinoprostone 10mg controlled-release vaginal device were included.Results: Among 216 included patients, 192 women (88.9%) achieved a cervical ripening after a single application of dinoprostone, while 24 (11.1%) required a second application. Patients notresponding to the first application of dinoprostone had a significantly higher body mass index (27.4 ± 6.7 kg/m2 vs 24.9 ± 5.2 kg/m2; p < 0.05) and a significant increase in gestational weight gain (14 ± 5.2 kg vs 11.6 ± 6.1; p < 0.005). Double application of dinoprostone resulted in spontaneousdelivery in 58.4% of cases, but it was related to poorer neonatal outcome, compared to a single application.Conclusions: Obese women, not responding to the first application of dinoprostone could respond to the second application of this vaginal prostaglandin. However, data related to the use of a double application are still very limited to recommend its use as a standardized procedurefor not responsive patients.

Keywords: Dinoprostone; labor induction; maternal factor; obesity; spontaneous delivery.

Publication types

  • Observational Study

MeSH terms

  • Administration, Intravaginal
  • Cervical Ripening / physiology
  • Cohort Studies
  • Dinoprostone*
  • Female
  • Humans
  • Infant, Newborn
  • Labor, Induced
  • Oxytocics* / therapeutic use
  • Pregnancy

Substances

  • Oxytocics
  • Dinoprostone